{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T20:01:42Z","timestamp":1791489702374,"version":"4.3.4"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,11,25]],"date-time":"2022-11-25T00:00:00Z","timestamp":1669334400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,11,25]],"date-time":"2022-11-25T00:00:00Z","timestamp":1669334400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Am J Cardiovasc Drugs"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1007\/s40256-022-00553-6","type":"journal-article","created":{"date-parts":[[2022,11,25]],"date-time":"2022-11-25T19:57:02Z","timestamp":1669406222000},"page":"19-33","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Adherence and Discontinuation of Disease-Specific Therapies for\u00a0Pulmonary Arterial Hypertension: A Systematic Review and Meta-Analysis"],"prefix":"10.1007","volume":"23","author":[{"given":"Sami","family":"Qadus","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdallah Y.","family":"Naser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6643-3269","authenticated-orcid":false,"given":"Richard","family":"Ofori-Asenso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zanfina","family":"Ademi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Safaa","family":"Al Awawdeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danny","family":"Liew","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,11,25]]},"reference":[{"issue":"1","key":"553_CR1","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1161\/CIRCRESAHA.115.301146","volume":"115","author":"YC Lai","year":"2014","unstructured":"Lai YC, Potoka KC, Champion HC, Mora AL, Gladwin MT. Pulmonary arterial hypertension: the clinical syndrome. Circ Res. 2014;115(1):115\u201330.","journal-title":"Circ Res"},{"key":"553_CR2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.j5492","volume":"360","author":"T Thenappan","year":"2018","unstructured":"Thenappan T, Ormiston ML, Ryan JJ, Archer SL. Pulmonary arterial hypertension: pathogenesis and clinical management. BMJ (Clinical research ed). 2018;360: j5492.","journal-title":"BMJ (Clinical research ed.)"},{"issue":"4","key":"553_CR3","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1378\/chest.15-0300","volume":"148","author":"HW Farber","year":"2015","unstructured":"Farber HW, Miller DP, Poms AD, Badesch DB, Frost AE, Muros-Le Rouzic E, Romero AJ, Benton WW, Elliott CG, McGoon MD, Benza RL. Five-year outcomes of patients enrolled in the REVEAL registry. Chest. 2015;148(4):1043\u201354.","journal-title":"Chest"},{"issue":"9","key":"553_CR4","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1016\/j.healun.2017.02.016","volume":"36","author":"H Gall","year":"2017","unstructured":"Gall H, Felix JF, Schneck FK, Milger K, Sommer N, Voswinckel R, et al. The giessen pulmonary hypertension registry: survival in pulmonary hypertension subgroups. J Heart Lung Transplant. 2017;36(9):957\u201367.","journal-title":"J Heart Lung Transplant"},{"issue":"119","key":"553_CR5","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1183\/09059180.00008210","volume":"19","author":"O Sitbon","year":"2010","unstructured":"Sitbon O, Gali\u00e8 N. Treat-to-target strategies in pulmonary arterial hypertension: the importance of using multiple goals. Eur Respir Rev. 2010;19(119):272\u20138.","journal-title":"Eur Respir Rev"},{"issue":"2","key":"553_CR6","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1378\/chest.14-0793","volume":"146","author":"DB Taichman","year":"2014","unstructured":"Taichman DB, Ornelas J, Chung L, Klinger JR, Lewis S, Mandel J, Palevsky HI, Rich S, Sood N, Rosenzweig EB, Trow TK, Yung R, Elliott CG, Badesch DB. Pharmacologic therapy for pulmonary arterial hypertension in adults: CHEST guideline and expert panel report. Chest. 2014;146(2):449\u201375.","journal-title":"Chest"},{"issue":"3","key":"553_CR7","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1111\/j.1547-5069.2003.tb00001.x","volume":"35","author":"PV Burkhart","year":"2003","unstructured":"Burkhart PV, Sabat\u00e9 E. Adherence to long-term therapies: evidence for action. J Nurs Scholarsh. 2003;35(3):207.","journal-title":"J Nurs Scholarsh"},{"issue":"7","key":"553_CR8","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1000097","volume":"6","author":"D Moher","year":"2009","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG. PRISMA Group, preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6(7): e1000097.","journal-title":"PLoS Med"},{"issue":"15","key":"553_CR9","doi-asserted-by":"publisher","first-page":"2008","DOI":"10.1001\/jama.283.15.2008","volume":"283","author":"DF Stroup","year":"2000","unstructured":"Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, Moher D, Becker BJ, Sipe TA, Thacker SB. Meta-analysis of observational studies in epidemiology: a proposal for reporting Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA. 2000;283(15):2008\u201312.","journal-title":"JAMA"},{"key":"553_CR10","unstructured":"Cochrane library. Cochrane Handbook for Systematic Reviews of Interventions. 2022 April 17, 2022]; Available from: https:\/\/training.cochrane.org\/handbook."},{"issue":"3","key":"553_CR11","doi-asserted-by":"publisher","first-page":"335","DOI":"10.2217\/fca.13.6","volume":"9","author":"JD Duarte","year":"2013","unstructured":"Duarte JD, Hanson RL, Machado RF. Pharmacologic treatments for pulmonary hypertension: exploring pharmacogenomics. Fut Cardiol. 2013;9(3):335\u201349.","journal-title":"Fut Cardiol"},{"key":"553_CR12","doi-asserted-by":"publisher","first-page":"S1767","DOI":"10.21037\/jtd.2019.09.14","volume":"11","author":"V Parikh","year":"2019","unstructured":"Parikh V, Bhardwaj A, Nair A. Pharmacotherapy for pulmonary arterial hypertension. J Thorac Dis. 2019;11:S1767\u201381.","journal-title":"J Thorac Dis"},{"issue":"3","key":"553_CR13","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1111\/jcpt.13515","volume":"47","author":"W Tesfaye","year":"2022","unstructured":"Tesfaye W, Peterson G. Self-reported medication adherence measurement tools: some options to avoid a legal minefield. J Clin Pharm Ther. 2022;47(3):363\u20138.","journal-title":"J Clin Pharm Ther"},{"issue":"1","key":"553_CR14","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1111\/j.1524-4733.2007.00213.x","volume":"11","author":"JA Cramer","year":"2008","unstructured":"Cramer JA, Roy A, Burrell A, Fairchild CJ, Fuldeore MJ, Ollendorf DA, et al. Medication compliance and persistence: terminology and definitions. Value Health. 2008;11(1):44\u20137.","journal-title":"Value Health."},{"key":"553_CR15","unstructured":"Wells, G., et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. 2022 April 17, 2022]; Available from: http:\/\/www.ohri.ca\/programs\/clinical_epidemiology\/oxford.asp."},{"issue":"11","key":"553_CR16","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1136\/jech-2013-203104","volume":"67","author":"JJ Barendregt","year":"2013","unstructured":"Barendregt JJ, Doi SA, Lee YY, Norman RE, Vos T. Meta-analysis of prevalence. J Epidemiol Commun Health. 2013;67(11):974\u20138.","journal-title":"J Epidemiol Commun Health"},{"key":"553_CR17","unstructured":"Higgins, J., et al. Cochrane Handbook for Systematic Reviews of Interventions version 6.0. 2019 July 2019; Available from: https:\/\/www.training.cochrane.org\/handbook."},{"key":"553_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/17534666211013688","volume":"15","author":"JC Coons","year":"2021","unstructured":"Coons JC, Crisamore K, Adams S, Modany A, Simon MA, Zhao W, Shaik IH, Venkataramanan R, Empey PE. A pilot study of oral treprostinil pharmacogenomics and treatment persistence in patients with pulmonary arterial hypertension. Ther Adv Respir Dis. 2021;15:1\u201311.","journal-title":"Ther Adv Respir Dis"},{"issue":"3","key":"553_CR19","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1007\/s40801-020-00183-x","volume":"7","author":"BB Dean","year":"2020","unstructured":"Dean BB, Saundankar V, Stafkey-Mailey D, Anguiano RH, Nelsen AC, Gordon K, Classi P. Medication adherence and healthcare costs among patients with pulmonary arterial hypertension treated with oral prostacyclins: a retrospective cohort study. Drugs Real World Outcomes. 2020;7(3):229\u201339.","journal-title":"Drugs Real World Outcomes"},{"issue":"1","key":"553_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/2045894019880086","volume":"10","author":"RP Frantz","year":"2020","unstructured":"Frantz RP, Hill JW, Lickert CA, Wade RL, Cole MR, Tsang Y, Drake W 3rd. Medication adherence, hospitalization, and healthcare resource utilization and costs in patients with pulmonary arterial hypertension treated with endothelin receptor antagonists or phosphodiesterase type-5 inhibitors. Pulmonary Circ. 2020;10(1):1\u201311.","journal-title":"Pulmonary Circ"},{"issue":"1","key":"553_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/2045893217743616","volume":"8","author":"D Grady","year":"2018","unstructured":"Grady D, Weiss M, Hernandez-Sanchez J, Pepke-Zaba J. Medication and patient factors associated with adherence to pulmonary hypertension targeted therapies. Pulmonary Circ. 2018;8(1):1\u20139.","journal-title":"Pulmonary Circ"},{"issue":"1","key":"553_CR22","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1007\/s41030-019-00106-4","volume":"6","author":"S Studer","year":"2020","unstructured":"Studer S, Hull M, Pruett J, Elliott C, Tsang Y, Drake W. Retrospective database analysis of treatment patterns among patients with pulmonary arterial hypertension. Pulmonary Therapy. 2020;6(1):79\u201392.","journal-title":"Pulmonary Therapy"},{"issue":"1","key":"553_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/2045894018816294","volume":"9","author":"S Studer","year":"2019","unstructured":"Studer S, Hull M, Pruett J, Koep E, Tsang Y, Drake W 3rd. Treatment patterns, healthcare resource utilization, and healthcare costs among patients with pulmonary arterial hypertension in a real-world US database. Pulmonary Circ. 2019;9(1):1\u201312.","journal-title":"Pulmonary Circ"},{"issue":"4","key":"553_CR24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1183\/23120541.00299-2020","volume":"6","author":"B Kjellstr\u00f6m","year":"2020","unstructured":"Kjellstr\u00f6m B, Sandqvist A, Hjalmarsson C, Nisell M, N\u00e4sman P, Ivarsson B. Adherence to disease-specific drug treatment among patients with pulmonary arterial hypertension or chronic thromboembolic pulmonary hypertension. ERJ Open Res. 2020;6(4):1\u201310.","journal-title":"ERJ Open Res"},{"issue":"2","key":"553_CR25","doi-asserted-by":"publisher","first-page":"206","DOI":"10.36469\/9812","volume":"5","author":"G Ruiz","year":"2018","unstructured":"Ruiz G, Yeaw J, Lickert CEA. Using real world evidence to describe pulmonary arterial hypertension treatment patterns, healthcare resource utilization, and costs associated with PDE-5 inhibitor monotherapy. J Health Econ Outcomes Res. 2018;5(2):206\u201319.","journal-title":"J Health Econ Outcomes Res."},{"issue":"6","key":"553_CR26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pone.0217798","volume":"14","author":"NB Shah","year":"2019","unstructured":"Shah NB, Mitchell RE, Proctor ST, Choi L, DeClercq J, Jolly JA, Hemnes AR, Zuckerman AD. High rates of medication adherence in patients with pulmonary arterial hypertension: an integrated specialty pharmacy approach. PLoS ONE. 2019;14(6):1\u201312.","journal-title":"PLoS ONE"},{"issue":"2","key":"553_CR27","doi-asserted-by":"publisher","first-page":"298","DOI":"10.3111\/13696998.2012.756399","volume":"16","author":"A Waxman","year":"2013","unstructured":"Waxman A, Chen SY, Boulanger L, Watson JA, Golden G. Factors associated with adherence to phosphodiesterase type 5 inhibitors for the treatment of pulmonary arterial hypertension. J Med Econ. 2013;16(2):298\u2013306.","journal-title":"J Med Econ"},{"issue":"8","key":"553_CR28","first-page":"834","volume":"24","author":"CD Burger","year":"2018","unstructured":"Burger CD, Ozbay AB, Lazarus HM, Riehle E, Montejano LB, Lenhart G, White RJ. Treatment patterns and associated health care costs before and after treatment initiation among pulmonary arterial hypertension patients in the United States. J Manag Care Spec Pharm. 2018;24(8):834\u201342.","journal-title":"J Manag Care Spec Pharm"},{"issue":"5","key":"553_CR29","doi-asserted-by":"publisher","first-page":"947","DOI":"10.3111\/13696998.2012.690801","volume":"15","author":"R Copher","year":"2012","unstructured":"Copher R, Cerulli A, Watkins A, Laura Monsalvo M. Treatment patterns and healthcare system burden of managed care patients with suspected pulmonary arterial hypertension in the United States. J Med Econ. 2012;15(5):947\u201355.","journal-title":"J Med Econ"},{"issue":"676","key":"553_CR30","first-page":"1","volume":"14","author":"M Sikirica","year":"2014","unstructured":"Sikirica M, Iorga SR, Bancroft T, Potash J. The economic burden of pulmonary arterial hypertension (PAH) in the US on payers and patients. BMC Health Serv Res. 2014;14(676):1\u201311.","journal-title":"BMC Health Serv Res"},{"issue":"6","key":"553_CR31","doi-asserted-by":"publisher","first-page":"2029","DOI":"10.1111\/crj.12770","volume":"12","author":"B Ivarsson","year":"2018","unstructured":"Ivarsson B, et al. Adherence and medication belief in patients with pulmonary arterial hypertension or chronic thromboembolic pulmonary hypertension: A nationwide population-based cohort survey. Clin Respir J. 2018;12(6):2029\u201335.","journal-title":"Clin Respir J"},{"issue":"6","key":"553_CR32","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1331\/JAPhA.2012.11088","volume":"52","author":"MA Chisholm-Burns","year":"2012","unstructured":"Chisholm-Burns MA, Spivey CA. The \u201ccost\u201d of medication nonadherence: consequences we cannot afford to accept. J Am Pharm Assoc. 2012;52(6):823\u20136.","journal-title":"J Am Pharm Assoc"},{"issue":"1","key":"553_CR33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1136\/bmjopen-2017-016982","volume":"8","author":"RL Cutler","year":"2018","unstructured":"Cutler RL, Fernandez-Llimos F, Frommer M, Benrimoj C, Garcia-Cardenas V. Economic impact of medication non-adherence by disease groups: a systematic review. BMJ Open. 2018;8(1):1\u201313.","journal-title":"BMJ Open"},{"issue":"5","key":"553_CR34","first-page":"1111","volume":"4","author":"AM Keogh","year":"2008","unstructured":"Keogh AM, Jabbour A, Hayward CS, Macdonald PS. Clinical deterioration after sildenafil cessation in patients with pulmonary hypertension. Vasc Health Risk Manag. 2008;4(5):1111\u20133.","journal-title":"Vasc Health Risk Manag"},{"issue":"2","key":"553_CR35","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1177\/1074248419877409","volume":"25","author":"S Narechania","year":"2020","unstructured":"Narechania S, Torbic H, Tonelli AR. Treatment discontinuation or interruption in pulmonary arterial hypertension. J Cardiovasc Pharmacol Ther. 2020;25(2):131\u201341.","journal-title":"J Cardiovasc Pharmacol Ther"},{"issue":"3","key":"553_CR36","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1080\/14737167.2021.1899814","volume":"22","author":"AY Naser","year":"2022","unstructured":"Naser AY. Cost-related nonadherence for prescription medications: a cross-sectional study in Jordan. Exp Rev Pharmacoecon Outcomes Res. 2022;22(3):497\u2013503.","journal-title":"Exp Rev Pharmacoecon Outcomes Res"},{"issue":"5","key":"553_CR37","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1136\/bmjopen-2013-004735","volume":"4","author":"M Kingman","year":"2014","unstructured":"Kingman M, Hinzmann B, Sweet O, Vachi\u00e9ry JL. Living with pulmonary hypertension: unique insights from an international ethnographic study. BMJ Open. 2014;4(5):1\u20137.","journal-title":"BMJ Open"},{"issue":"3","key":"553_CR38","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1007\/s10865-007-9147-y","volume":"31","author":"KS Ingersoll","year":"2008","unstructured":"Ingersoll KS, Cohen J. The impact of medication regimen factors on adherence to chronic treatment: a review of literature. J Behav Med. 2008;31(3):213\u201324.","journal-title":"J Behav Med"},{"key":"553_CR39","doi-asserted-by":"crossref","first-page":"A138","DOI":"10.1136\/ejhpharm-2016-000964","volume":"24","author":"J Su\u00e1rez","year":"2017","unstructured":"Su\u00e1rez J, et al. DI-058 Risk of drug\u2013drug interactions in a pulmonary arterial hypertension population. Eur J Hosp Pharm. 2017;24:A138.","journal-title":"Eur J Hosp Pharm"},{"issue":"2","key":"553_CR40","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1331\/JAPhA.2013.12202","volume":"53","author":"L Dayer","year":"2013","unstructured":"Dayer L, Heldenbrand S, Anderson P, Gubbins PO, Martin BC. Smartphone medication adherence apps: potential benefits to patients and providers. J Am Pharm Assoc. 2013;53(2):172\u201381.","journal-title":"J Am Pharm Assoc"},{"issue":"98","key":"553_CR41","first-page":"1","volume":"12","author":"AS Gadkari","year":"2012","unstructured":"Gadkari AS, McHorney CA. Unintentional non-adherence to chronic prescription medications: how unintentional is it really? BMC Health Serv Res. 2012;12(98):1\u201312.","journal-title":"BMC Health Serv Res"},{"issue":"4","key":"553_CR42","doi-asserted-by":"publisher","first-page":"228","DOI":"10.21693\/1933-088X-8.4.228","volume":"8","author":"T Stewart","year":"2010","unstructured":"Stewart T. Facilitating PAH medication adherence: patient centered management. Adv Pul Hypertension. 2010;8(4):228\u201331.","journal-title":"Adv Pul Hypertension."},{"key":"553_CR43","unstructured":"Sourounis E, Kyrychenko P et al. Effects of face-to-face educational nursing support on patient compliance with oral PAH therapies. 2021."},{"issue":"1","key":"553_CR44","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.amjopharm.2011.02.004","volume":"9","author":"WF Gellad","year":"2011","unstructured":"Gellad WF, Grenard JL, Marcum ZA. A systematic review of barriers to medication adherence in the elderly: looking beyond cost and regimen complexity. Am J Geriatr Pharmacother. 2011;9(1):11\u201323.","journal-title":"Am J Geriatr Pharmacother"},{"issue":"2","key":"553_CR45","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/j.cger.2012.01.008","volume":"28","author":"ZA Marcum","year":"2012","unstructured":"Marcum ZA, Gellad WF. Medication adherence to multidrug regimens. Clin Geriatr Med. 2012;28(2):287\u2013300.","journal-title":"Clin Geriatr Med"},{"issue":"7","key":"553_CR46","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/pharmaceutics13071100","volume":"13","author":"K Kvarnstr\u00f6m","year":"2021","unstructured":"Kvarnstr\u00f6m K, Westerholm A, Airaksinen M, Liira H. Factors contributing to medication adherence in patients with a chronic condition: a scoping review of qualitative research. Pharmaceutics. 2021;13(7):1\u201341.","journal-title":"Pharmaceutics"},{"key":"553_CR47","first-page":"11","volume":"2","author":"RB Haynes","year":"2008","unstructured":"Haynes RB, Ackloo E, Sahota N, McDonald HP, Yao X. Interventions for enhancing medication adherence. Cochrane Database Syst Rev. 2008;2:11.","journal-title":"Cochrane Database Syst Rev"},{"issue":"4","key":"553_CR48","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1007\/s13142-015-0315-2","volume":"5","author":"MJ Stirratt","year":"2015","unstructured":"Stirratt MJ, Dunbar-Jacob J, Crane HM, Simoni JM, Czajkowski S, Hilliard ME, et al. Self-report measures of medication adherence behavior: recommendations on optimal use. Transl Behav Med. 2015;5(4):470\u201382.","journal-title":"Transl Behav Med."}],"container-title":["American Journal of Cardiovascular Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40256-022-00553-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40256-022-00553-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40256-022-00553-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,17]],"date-time":"2023-01-17T12:08:53Z","timestamp":1673957333000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40256-022-00553-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,25]]},"references-count":48,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1]]}},"alternative-id":["553"],"URL":"https:\/\/doi.org\/10.1007\/s40256-022-00553-6","relation":{},"ISSN":["1175-3277","1179-187X"],"issn-type":[{"value":"1175-3277","type":"print"},{"value":"1179-187X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,25]]},"assertion":[{"value":"4 October 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 November 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"AYN and RO-A conceptualised the study. SQ, AYN, SAA, and RO-A collected the data. All the authors participated in the drafting of this manuscript and provided final approval of the submitted version of the article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}},{"value":"No funding or sponsorship was received for this study or publication of this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"All data generated or analysed during this study are included in this published article.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and materials"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"Richard Ofori-Asenso is a current employee of AstraZeneca\u00a0Plc. The views expressed in this article are his own and do not represent that of his employers. Sami Qadus, Abdallah Y. Naser, Zanfina Ademi, Safaa Al Awawdeh, and Danny Liew declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}